Formulated for parkinson's disease to manage motor symptoms and support neurological stability.
Mechanism of Action
Levodopa is converted to dopamine in the brain. Carbidopa inhibits the peripheral decarboxylation of levodopa, allowing more of it to reach the central nervous system and reducing peripheral side effects like nausea.
Route of Administration
Oral
Onset Time
30–60 minutes
Duration
4–6 hours
Contraindications
Concurrent use of non-selective MAO inhibitors, Narrow-angle glaucoma, History of melanoma
Severe Adverse Events
Neuroleptic malignant syndrome, Hallucinations, Anaphylaxis — requires immediate medical attention
Common Side Effects
Nausea, Dizziness, Headache
Uncommon Side Effects
Dyskinesia, Insomnia, Orthostatic hypotension
Drug Interactions
Alcohol, MAO Inhibitors, Iron Supplements, Phenytoin, Metoclopramide
Pregnancy Safety Warnings
FDA Category C: Use only if potential benefit outweighs risk. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Carbidopa with Levodopa is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
